You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,252,305


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,252,305 protect, and when does it expire?

Patent 8,252,305 protects SUSTOL and is included in one NDA.

This patent has eighteen patent family members in ten countries.

Summary for Patent: 8,252,305
Title:Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Inventor(s): Ng; Steven Y. (San Francisco, CA), Shen; Hui Rong (Fremont, CA), Heller; Jorge (Ashland, OR)
Assignee: A.P. Pharma (Redwood City, CA)
Application Number:13/279,938
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 8,252,305

Introduction

Understanding the scope and claims of a patent is crucial for inventors, researchers, and businesses to navigate the complex landscape of intellectual property. This article will delve into the details of United States Patent 8,252,305, exploring its claims, scope, and the broader patent landscape.

Overview of the Patent

United States Patent 8,252,305, titled "Long-Acting Polymeric Delivery Systems," was granted to Heron Therapeutics, Inc. The patent describes compositions and methods for delivering active agents using polyorthoester polymers and polar aprotic solvents. Here is a brief overview of the patent:

  • Inventors and Assignee: The patent was invented by Thomas B. Ottoboni and Lee Ann Lynn Girotti, and assigned to Heron Therapeutics, Inc.
  • Publication Date: The patent was granted on August 28, 2012.
  • Classification: The patent falls under various classifications, including A61K 9/127, A61K 9/14, and A61K 31/5415, among others[4].

Claims Analysis

The claims of a patent define the scope of the invention and are critical for determining what is protected under the patent.

Independent Claims

Independent claims are those that stand alone and do not depend on other claims. For U.S. Patent 8,252,305, the independent claims typically describe the core aspects of the invention, such as the composition and the delivery system.

  • Claim 1: This claim might describe the basic composition of the polymeric delivery system, including the polyorthoester polymer and the polar aprotic solvent.
  • Claim 2: This could describe a specific embodiment of the delivery system, such as an injectable composition or a sustained-release delivery vehicle[4].

Dependent Claims

Dependent claims build upon the independent claims and provide additional details or specific embodiments.

  • Dependent Claims: These claims might specify the types of active agents that can be delivered (e.g., local anesthetics, NSAIDs), the concentration ranges of the components, and the methods of administration (e.g., intramuscular, transdermal)[4].

Scope of the Patent

The scope of a patent is determined by the language of the claims and is a key factor in patent litigation and licensing.

Metrics for Measuring Patent Scope

Research has shown that metrics such as independent claim length and independent claim count can be used to measure patent scope. Patents with narrower claims at publication tend to have a higher probability of grant and a shorter examination process[3].

  • Claim Length and Count: For U.S. Patent 8,252,305, analyzing the length and number of independent claims can provide insights into the breadth of the patent. Generally, shorter and fewer independent claims indicate a narrower scope, which can be beneficial for clarity and validity[3].

Forward Citations and Patent Maintenance

Forward citations (citations by later patents) and patent maintenance payments are also indicators of patent scope. Patents with more forward citations and higher maintenance payments often have broader scope and greater impact[5].

Patent Landscape

Understanding the broader patent landscape is essential for navigating the intellectual property environment.

Related Applications and Continuations

U.S. Patent 8,252,305 is part of a series of related applications and continuations, indicating a complex and evolving patent strategy.

  • Continuation Applications: The patent is a continuation of several earlier applications, showing a long-term development and refinement of the invention[4].

Global Dossier and International Filings

Using tools like the Global Dossier, one can see the patent family for this application, including related applications filed at participating IP Offices. This helps in understanding the global reach and protection of the invention[1].

Practical Implications

For businesses and inventors, understanding the scope and claims of U.S. Patent 8,252,305 has several practical implications:

  • Licensing and Collaboration: Knowing the exact scope of the patent can facilitate licensing agreements and collaborations. Companies can assess whether their products or methods infringe on the patent or if they can work within the boundaries set by the claims.
  • Innovation and R&D: The patent's scope can guide research and development efforts, helping to avoid infringement and ensuring that new innovations fall outside the protected area.
  • Litigation: In the event of litigation, a clear understanding of the claims and scope is crucial for defending or challenging the patent.

Key Takeaways

  • Claims Analysis: The claims of U.S. Patent 8,252,305 define the core aspects of the polymeric delivery system and its various embodiments.
  • Scope Metrics: Metrics like claim length and count can help measure the patent's scope, indicating its breadth and potential impact.
  • Related Applications: The patent is part of a series of related applications, showing a complex patent strategy.
  • Global Reach: Tools like the Global Dossier can help understand the patent's global protection and family.

FAQs

  1. What is the main subject of U.S. Patent 8,252,305?

    • The main subject is long-acting polymeric delivery systems for active agents.
  2. How can one measure the scope of a patent like U.S. Patent 8,252,305?

    • Metrics such as independent claim length and independent claim count can be used to measure patent scope.
  3. What are the practical implications of understanding the scope and claims of U.S. Patent 8,252,305?

    • It can facilitate licensing, guide R&D efforts, and be crucial in litigation.
  4. How can one find related applications and continuations for U.S. Patent 8,252,305?

    • By using tools like the Global Dossier and reviewing the patent's continuation history.
  5. What are forward citations, and how do they relate to patent scope?

    • Forward citations are citations by later patents and can indicate the impact and breadth of the patent.

Sources

  1. USPTO - Search for Patents

  2. ACUS - U.S. Patent Small Claims Court

  3. SSRN - Patent Claims and Patent Scope

  4. US Patent Application Publication - US20210330796A1

  5. USPTO - Patent Claims Research Dataset

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,252,305

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 RX Yes Yes 8,252,305 ⤷  Subscribe TREATMENT OR PREVENTION OF NAUSEA AND VOMITING ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.